retatrutide phase 2 trial dosing schedule clinical retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Trial Data Dosing : – retatrutide dosing schedule phase 2

Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

The inclusion of a 9mg dose tier is noteworthy because it was not tested in Phase 2

Intestinal phase of gastric secretion', Journal of Experimental Physiology , 15,55-68

Diabetes Care (2014) 37:216876

Demand for such drugs is likely to continue to be strong in the future due to rising rates of obesity and interlinked chronic diseases

PK and PD analysis The PK of AMG 133 was evaluated using a validated liquid-chromatography tandem mass spectrometry (LCMS/MS) methodology to detect total AMG 133, defined as the GIPR-Ab with or without the GLP-1 analogue peptides and intact AMG 133, defined as the GIPR-Ab with at least one attached GLP-1 analogue peptide